Search

Displaying results 6461 - 6470 of 10000 in total
  1. Drug

    Neocartilage

    go.drugbank.com/drugs/DB05257
    Investigational

    Neocartilage is the only scaffold-free living cartilage graft on the market.

  2. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

  3. Drug

    EGT-301

    go.drugbank.com/drugs/DB17649
    Experimental

    It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome

  4. Drug

    Pateclizumab

    go.drugbank.com/drugs/DB14997
    Investigational

    Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared

  5. Drug

    Zonampanel anhydrous

    go.drugbank.com/drugs/DB20448
    Investigational

    Zonampanel anhydrous is under investigation in clinical trial NCT00044070 (A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients).

  6. Drug

    Risovalisib

    go.drugbank.com/drugs/DB21474
    Investigational

    Risovalisib is under investigation in clinical trial NCT05043922 (A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma).

  7. Drug

    Ethyl macadamiate

    go.drugbank.com/drugs/DB11243
    Approved

    It is a non-volatile ester of ethyl alcohol and the fatty acids.

  8. Drug

    Nisoxetine

    go.drugbank.com/drugs/DB09186
    Experimental

    Nisoxetine is a selective norepinephrine reuptake inhibitor (SNRI) developed in the 1970s. … It has been used to research obesity and energy balance, and exerts some local analgesia effects.

  9. Drug

    ATG-101

    go.drugbank.com/drugs/DB17162
    Investigational

    ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors

  10. Drug

    RO7296682

    go.drugbank.com/drugs/DB17531
    Investigational

    RO7296682 is a monoclonal antibody against CD25 (IL-2R alpha) expressed on tumour-infiltrating regulatory T (T<sub>reg</sub>) cells. … RO7296682 is under investigation in clinical trial NCT04642365 (A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.